175 related articles for article (PubMed ID: 27733071)
21. BCR-ABL1 compound mutations drive ponatinib resistance.
Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
[TBL] [Abstract][Full Text] [Related]
22. The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sanford DS; Kantarjian H; O'Brien S; Jabbour E; Cortes J; Ravandi F
Expert Rev Anticancer Ther; 2015 Apr; 15(4):365-73. PubMed ID: 25764322
[TBL] [Abstract][Full Text] [Related]
23. Ponatinib--a step forward in overcoming resistance in chronic myeloid leukemia.
Frankfurt O; Licht JD
Clin Cancer Res; 2013 Nov; 19(21):5828-34. PubMed ID: 23935038
[TBL] [Abstract][Full Text] [Related]
24. [Vascular adverse events of ponatinib during treatment of Philadelphia chromosome-positive leukemia: a retrospective single-institution analysis].
Sato N; Yuda J; Yamauchi N; Miyamoto K; Kamihara Y; Minami Y
Rinsho Ketsueki; 2019; 60(12):1623-1629. PubMed ID: 31902811
[TBL] [Abstract][Full Text] [Related]
25. Unexpected Success of Watch and Wait Strategy in a Ponatinib-Intolerant Patient With Chronic Myeloid Leukemia.
Engel NW; Constantin A; Fowlkes S; Assouline S
J Oncol Pract; 2016 Jun; 12(6):592-4. PubMed ID: 27246687
[No Abstract] [Full Text] [Related]
26. Should vascular effects of newer treatments be addressed more completely?
Yang EH; Watson KE; Herrmann J
Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
[No Abstract] [Full Text] [Related]
27. [Ponatinib: new option for the treatment of resistant chronic myeloid leukemia].
Camañas-Troyano C; Calderón-Acedos C; Moriel-Sánchez Mdel C; Segura-Bedmar M
Farm Hosp; 2013; 37(5):428-9. PubMed ID: 24128110
[No Abstract] [Full Text] [Related]
28. Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity.
Boo YL; Liam CCK; Toh SG; Lim SM
Hong Kong Med J; 2019 Apr; 25(2):162-163. PubMed ID: 30971509
[No Abstract] [Full Text] [Related]
29. Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis.
Kayabasi C; Caner A; Yilmaz Susluer S; Balci Okcanoglu T; Ozmen Yelken B; Asik A; Mutlu Z; Caliskan Kurt C; Goker Bagca B; Biray Avci C; Sahin F; Saydam G; Gunduz C
Med Oncol; 2022 Jan; 39(3):29. PubMed ID: 35059859
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
[TBL] [Abstract][Full Text] [Related]
31. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.
Müller MC; Cervantes F; Hjorth-Hansen H; Janssen JJWM; Milojkovic D; Rea D; Rosti G
Crit Rev Oncol Hematol; 2017 Dec; 120():52-59. PubMed ID: 29198338
[TBL] [Abstract][Full Text] [Related]
32. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
[TBL] [Abstract][Full Text] [Related]
33. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
[TBL] [Abstract][Full Text] [Related]
34. Success is built on failures: tackling the challenge of ponatinib failure.
Hiwase D; Ross D
Leuk Lymphoma; 2018 Jun; 59(6):1279-1281. PubMed ID: 29382246
[No Abstract] [Full Text] [Related]
35. Synthesis of ponatinib analogues as novel inhibitors of leukemia stem cells.
Wang L; Zhao XJ; Hua C; Wu HX; Bai CG; Chen Y
Future Med Chem; 2022 May; 14(9):623-645. PubMed ID: 35332794
[No Abstract] [Full Text] [Related]
36. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
37. Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.
Goker B; Caliskan C; Onur Caglar H; Kayabasi C; Balci T; Erbaykent Tepedelen B; Aygunes D; Yilmaz Susluer S; Mutlu Z; Selvi Gunel N; Korkmaz M; Saydam G; Gunduz C; Biray Avci C
J BUON; 2014; 19(4):992-8. PubMed ID: 25536607
[TBL] [Abstract][Full Text] [Related]
38. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
39. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lipton JH; Chuah C; Guerci-Bresler A; Rosti G; Simpson D; Assouline S; Etienne G; Nicolini FE; le Coutre P; Clark RE; Stenke L; Andorsky D; Oehler V; Lustgarten S; Rivera VM; Clackson T; Haluska FG; Baccarani M; Cortes JE; Guilhot F; Hochhaus A; Hughes T; Kantarjian HM; Shah NP; Talpaz M; Deininger MW;
Lancet Oncol; 2016 May; 17(5):612-21. PubMed ID: 27083332
[TBL] [Abstract][Full Text] [Related]
40. Early diagnosis, clinical management, and follow-up of cardiovascular events with ponatinib.
Casavecchia G; Galderisi M; Novo G; Gravina M; Santoro C; Agricola E; Capalbo S; Zicchino S; Cameli M; De Gennaro L; Righini FM; Monte I; Tocchetti CG; Brunetti ND; Cadeddu C; Mercuro G
Heart Fail Rev; 2020 May; 25(3):447-456. PubMed ID: 32026180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]